Tumor markers of bladder cancer: The schistosomal bladder tumors versus non-schistosomal bladder tumors

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Abdulamir, Ahmed S ^a   Hafidh, Rand R ^a   Kadhim, Haider S ^a   Abubakar, Fatimah ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MOLECULAR MARKER; MYC PROTEIN; PROTEIN BNIP3; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SCHISTOSOMAL BLADDER TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMAL BLADDER TUMOR; SQUAMOUS CELL CARCINOMA; SYMPTOMATOLOGY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR BIOPSY; TUMOR GROWTH; URINE CYTOLOGY; ANIMAL; BIOSYNTHESIS; BLADDER TUMOR; CASE CONTROL STUDY; DISEASE COURSE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PARASITOLOGY; PATHOLOGY; PROGNOSIS; RISK FACTOR; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA;

ADULT; AGED; ANIMALS; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CYSTITIS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 64949136454     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-27     Document Type: Article

References (38)

1. Etiology of bladder cancer. T Shirai, Semin Urol 1993 3 113 116
2. Urothelial Carcinoma: Cancers of the Bladder Ureter & Renal Pelvis. PR Carroll, General Urology Philadelphia: Prentice-Hall International Inc, Tanagho EA, McAninch JW, 14 1995 353 372
3. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. AA Sandberg CS Berger, J Urol 1994 151 545 560 7905930
4. The epidemiology and control of schistosomiasis in Africa. GC Ejezie, Nigeria J Med 1991 1 29 30
5. The epidemiology of schistosomiasis in Egypt: Gharbia Governorate. MA El-Harvey MM Amr AB Abdel-Rahman, Am J Trop Med Hyg 2000 62 42 48 10813499
6. Relationship between schistosomiasis and bladder cancer. MH Mostafa SA Sheweita PJ O'Connor, Clin Microbiol Rev 1999 12 97 111 9880476
7. Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. W Warren PJ Biggs M el-Baz MA Ghoneim MR Stratton S Venitt, Carcinogenesis 1995 16 1181 1189 10.1093/carcin/16.5.1181 7767983
8. Differential hypomethylation of the c- myc protooncogene in bladder cancers at different stages and grades. L Del Senno I Maestri R Piva S Hanau A Reggiani A Romano G Russo, J Urol 1989 142 146 149 2733094
9. Molecular markers for diagnosis, staging and prognosis of bladder cancer. SG Williams M Buscarini JP Stein, Oncology 2001 15 1461 1484 11758874
10. Targeting EGFR in bladder cancer. GJ Villares M Zigler K Blehm C Bogdan D McConkey D Colin M Bar-Eli, World J Urol 2007 25 573 579 10.1007/s00345-007- 0202-7 17690890
11. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo. AJ Colquhoun LA McHugh E Tulchinsky M Kriajevska JK Mellon, J Radiat Res (Tokyo) 2007 48 351 360 10.1269/jrr.07014 17609586
12. p53 and retinoblastoma pathways in bladder cancer. AP Mitra M Birkhahn RJ Cote, World J Urol 2007 25 563 571 10.1007/s00345-007-0197-0 17710407
13. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. TS Tzai YS Tsai NH Chow, Urol Oncol 2004 22 112 118 15082007
14. The role of p53 in apoptosis and cancer. CO Bellamy R Malcomson A Wyllie, Apoptosis and cancer Basel: Karger Landes systems, Martin SJ, 2 1997 67 71
15. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells. HJ Cho JK Kim KD Kim HK Yoon MY Cho YP Park JH Jeon ES Lee SS Byun HM Lim, Cancer Lett 2006 237 56 66 10.1016/j.canlet.2005.05.039 16009487
16. Bcl-2 Family proteins: Role in dysregulation of apoptosis and chemoresistance in cancer. JC Reed, Apoptosis and cancer Basel: Karger Landes systems, Martin SJ, 2 1997 112 116
17. Comparison of Ki-67 equivalent antibodies. CF Lindboe SH Torp, J Clin Pathol 2002 55 467 471 12037032
18. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. M Srinivasan D Sedmak S Jewell, Am J Pathol 2002 161 1961 1971 12466110
19. The impact of schistosomiasis on the pathology of bladder carcinoma. MN El Bolkainy NM Mokhtar MA Ghoneim MH Hussein, Cancer 1981 48 2643 2648 10.1002/1097-0142(19811215)48:12<2643::AID-CNCR2820481216>3.0.CO;2-C 7306921
20. Carcinoma of the urinary bladder associated with schistosomiasis in Egypt: the possible causal relationship. HN Tawfik, Princess Takamatsu Symp 1987 18 197 209 3147281
21. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm. A Pich M Margaria L Chiusa P Bortolin G Palestro, Oncology Reports 2003 10 1329 1335 12883702
22. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder. KS Chaudhary QL Lu PD Abel N Khandan-Nia AM Shoma M el Baz GW Stamp EN Lalani, Br J Urol 1997 79 78 84 9043502
23. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). KM Badr JD Nolen PB Derose C Cohen, Hum Pathol 2004 35 2 184 189 10.1016/j.humpath.2003.10.006 14991535
24. bcl-2 and p53 overexpression as associated risk factors in TCC of the bladder. F Atug L Turkeri M Ozyurek A Akdas, Int Urol Nephrol 1998 30 455 461 10.1007/BF02550226 9821049
25. Human papilloma virus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. A Helal Tel MT Fadel NK El-Sayed, Pathol Oncol Res 2006 12 3 173 178 10.1007/BF02893365 16998598
26. p53 as a prognostic marker for bladder cancer: a meta-analysis and review. N Malats A Bustos CM Nascimento F Fernandez M Rivas D Puente M Kogevinas FX Real, Lancet Oncol 2005 6 678 686 10.1016/S1470-2045(05)70315-6 16129368
27. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. A Haitel B Posch M El-Baz AA Mokhtar M Susani MA Ghoneim M Marberger, J Urol 2001 165 5 1481 1487 10.1016/S0022-5347(05)66332-X 11342901
28. Deletion of p16 and p15 genes In schistosomiasis-associated bladder cancer (SABC). S Eissa R Ali-Labib A Khalifa, Clin Chim Acta 2000 300 159 169 10.1016/S0009-8981(00)00317-X 10958872
29. Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers. A Brunner I Verdorfer M Prelog C Mayerl G Mikuz A Tzankov, Pathobiology 2008 75 25 33 10.1159/000113792 18334837
30. Molecular events underlying schistosomiasis-related bladder cancer. N Ramchurren K Cooper IC Summerhayes, Int J Cancer 1995 62 237 244 10.1002/ijc.2910620302 7628866
31. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. SJ Chatterjee B George PJ Goebell M Alavi-Tafreshi SR Shi YK Fung PA Jones C Cordon-Cardo RH Datar RJ Cote, J Pathol 2004 203 762 770 10.1002/path.1567 15221935
32. Bcl-XL and Bcl-2 expression in bilharzial squamous cell carcinoma of the urinary bladder: which protein is prognostic? DA Hameed AM Abdel Raheem E Mosad HM Hammouda NA Kamel MA Abdel Aziz, Urology 2008 72 2 374 378 10.1016/j.urology.2007.12.063 18342927
33. c-myc in bladder cancer, clinical findings and analysis of mechanism. BJ Schmitz-Drager WA Schulz B Jurgens CD Gerharz CR van Roeyen H Bultel, Urol Res 1997 25 S45 S49 10.1007/BF00942047 9079756
34. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. PK Lipponen, J Pathol 1995 175 203 210 10.1002/path.1711750208 7738716
35. Patterns of expressions of transforming growth factor and epidermal growth factor receptor in squamous cell lesions of the urinary bladder. MF Tungekar J Linehan, J Clin Pathol 1998 51 583 587 9828815 10.1136/jcp.51.8.583
36. [Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncoprotein in the prognosis for the clinical course of bladder cancer]. EA Masliukova KM Pozharisskii MI Karelin V Startsev VP Ten, Vopr Onkol 2006 52 643 648 17338241
37. The prevalence of bcl-2, p53 and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. L Nakopoulou C Vourlakou A Zervas, Hum Pathol 1998 29 146 154 10.1016/S0046-8177(98)90225-8 9490274
38. Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence. C Pfister L Moore P Allard H Larue Y Fradet, Clini Ca Res 1999 5 4079 4084 10632343